Mortality of COPD Patients Infected with Multi-Resistant Pseudomonas aeruginosa: A Case and Control Study
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The incidence of infections caused by multiresistant Pseudomonas aeruginosa (MDRP) is increasing, especially in critically ill patients. The relevance of MDRP in the prognosis of chronic obstructive pulmonary disease (COPD) acute exacerbation in patients admitted to the hospital’s general ward is not well known.
Patients and Methods:
Case and control study. Cases were patients admitted for COPD acute exacerbation in which a MDRP was isolated from spontaneous sputum. MDRP was defined as the absence of susceptibility to three or more antibiotic families (betalactams, quinolones, carbapenems and aminoglycosides). Patients currently or previously admitted to the intensive care unit (ICU), who had a recent surgery, neoplasia or immunosuppressive treatment were excluded from the study. Patients from the control group were admitted for COPD acute exacerbation and matched 1:1 with each case-patient in terms of age, sex, date of admission and degree of airway obstruction. Pseudomonas aeruginosa susceptible to all antimicrobials or other microorganisms was isolated from sputum.
During the study period (2000–2005), 50 casepatients and 50 controls were included. Crude mortality at 2 years was 60% for the case-patients and 28% for the control group. In the logistic regression analysis adjusted for age, FEV1 and number of previous hospital admissions, MDRP infection was associated to an increased mortality in comparison to patients without MDRP (OR = 6.2; IC 95%: 1.7–22.1; p < 0.01).
In COPD patients admitted to the general ward, acute exacerbation with MDRP in sputum was associated with higher mortality.
- Goldberg JB, Hancock RE, Parales RE, Loper J, Cornelis P: Pseudomonas 2007. J Bacteriol 2008; 190: 2649–2662. CrossRef
- Pollack M: Pseudomonas aeruginosa. In: Mandell GL (ed.), Mandell, Douglas and Bennett’s principles and practice of infectious diseases (5th edn). Churchill Livingstone, Philadelphia 2000, pp 2310–2335.
- Livermore DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst night-mare? Clin Infect Dis 2002; 34: 634–640. CrossRef
- Carmeli Y, Troillet N, Eliopoulos GM, Samore MH: Emergence of antibiotic resistant Pseudomonas aeruginosa: comparison of risk associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379–1382.
- García Rodríguez JA, Casal M, Rodríguez F, Grupo de estudio de sensibilidad antibiótica: Evolución de la resistencia antibiótica de Pseudomonas aeruginosa, Echerichia coli y Bacteroides fragilis (1997–2001) Rev. Española Quimioterap 2003; 16: 421–427.
- Ohmagari N, Hanna H, Graviss L, Hackett B, Perego C, González V, Dvorak T, Hogan H, Hachem R, Rolston K, Raad I: Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 2005; 104: 205–212. CrossRef
- Lieberman D, Lieberman D: Pseudomonal infections in patients with COPD: epidemiology and management. Am J Respir Med 2003; 2: 459–468.
- Cao B, Wang H, Sun H, Zhu Y, Chen M: Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004; 57: 112–118. CrossRef
- Ferrer M, Ioanas M, Arancibia F, Marco MA, de la Bellacasa JP, Torres A: Microbial airway colonisation is associated with noninvasive ventilation failure in exacerbation of chronic obstructive pulmonary disease. Crit Care Med 2005; 33: 2003–2009. CrossRef
- Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, de la Torre MV, Sirvent JM, Bodi M: Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Resp J 2006; 27: 1210–1216. CrossRef
- Troillet N, Samore MH, Carmeli Y: Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25: 1094–1098. CrossRef
- Cunha BA: Pseudomonas aeruginosa: resistance and therapy. Semin Respir Infect 2002; 17: 231–239. CrossRef
- Gasink L, Fishman N, Weiner M, Nachamkin I, Bilker W, Lautenbach E: Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 2006; 119: 526–529. CrossRef
- Cappelletty DM: Comparison of methodologies for synergism testing of drug combinations against resistant strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 677–683.
- Rosell A, Monso E, Soler N, Torres F, Angrill J, Riise G, Zalacain R, Morera J, Torres A: Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 25: 891–897. CrossRef
- Ko FW, Ip M, Chan PK, Fok JP, Chn MC, Ngai JC, Chan DP, Hui DS: A 1-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD. Chest 2007; 131: 44–52. CrossRef
- Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M: Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40–46. CrossRef
- Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA: Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1090–1095. CrossRef
- Friedland I, Gallagher G, King T, Woods GL: Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter intensive care unit surveillance study (ISS) in the United States. J Chemother 2004; 16: 437–441.
- National Heart, Lung and Blood Institute, World Health Organization: Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; updated 2004. National Heart, Lung, and Blood Institute, Bethesda, 2004.
- Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA: Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759–764. CrossRef
- Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E, Nieminen MM, Aine T, Bakke P, Janson C: Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006; 7: 109. CrossRef
- Almagro P, Calbo E, de Ochoa Echaguen A, Barreiro B, Quintana S, Heredia JL, Garau J: Mortality after hospitalization for COPD. Chest 2002; 121: 1441–1448. CrossRef
- Groenewegen KH, Schols AM, Wouters EFM: Mortality, mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459–467. CrossRef
- Connors AF, Dawson NV, Thomas C, Connors AF Jr, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA: Outcomes following acute exacerbation of severe chronic obstructive disease. Am J Respir Crit Care Med 1996; 154: 959–967.
- Chua AP, Kang-Hoe L, Tow-Keang L: In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD. A Retrospective Study. Chest 2005; 128: 518–524. CrossRef
- Lode H, Allewelt M, Balk S, De Roux A, Mauch H, Niederman M, Schmidt-Ioanas M: A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35: 143–149. CrossRef
- Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro B, Graffunder E, McNutt LA: Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Antimicrob Agents Chemother 2007; 51: 417–422. CrossRef
- Eller J, Ade A, Schberg T, Niederman MS, Mauch H, Lode H: Infective exacerbations of chronic bronchitis: relation between bacteriologic aetiology and lung function. Chest 1998; 113: 1542–1548. CrossRef
- Nseir S, Di Pompeo C, Cavestri B, Jozefowicz E, Nyunga M, Soubrier S, Roussel-Delvallez M, Saulnier F, Mathieu D, Durocher A: Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit Care Med 2006; 34: 2959–2966.
- Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, Sethi S: Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 853–860. CrossRef
- Mortality of COPD Patients Infected with Multi-Resistant Pseudomonas aeruginosa: A Case and Control Study
Volume 37, Issue 1 , pp 16-19
- Cover Date
- Print ISSN
- Online ISSN
- Urban and Vogel
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Dept. of Internal Medicine and Infectious Diseases, Hospital del Mar, Autonomous University of Barcelona, Paseo Marítimo 25-29, 08003, Barcelona, Spain
- 2. Dept. of Pneumology, Hospital del Mar, Barcelona, Spain
- 3. Muscular and Respiratory Research Unit (URMAR), Municipal Institute of Medical Research (IMIM), IMIM-Hospital del Mar-CIBER de Enfermedades Respiratorias, ISC III, Pompeu Fabra CEXS-University, Barcelona, Spain
- 4. Dept. of Microbiology, Laboratorio de Referencia de Catalunya, Barcelona, Spain